Letters
“Liquid biopsy” for cancer screening
Grail’s reply to editorial on “liquid biopsy” for cancer screening
BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n596 (Published 03 March 2021) Cite this as: BMJ 2021;372:n596
- Harpal Kumar, president
- Grail Europe, New Penderel House, London WC1V 7HP, UK
- hkumar{at}grailbio.com
I write in response to some of the key points raised in Barclay and Bradley’s editorial regarding the partnership between Grail and NHS England.1
Grail’s multi-cancer early detection (MCED) test represents one of the first examples of an innovation developed by a private company but intended for public health uptake. Adding MCED to ongoing single cancer screening could dramatically improve …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £164 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.